April 1, 2026
IN THIS ISSUE / April 1, 2026
Aesthetic treatment considerations for perimenopausal, menopausal patients
DermWorld Insights and Inquiries: Cocaine-associated plasma cell orificial mucositis — Anything goes
Effects of PRP, minoxidil in patients with androgenetic alopecia
Vaccination recommendations in patients with atopic dermatitis taking JAK inhibitors
Aesthetic treatment considerations for perimenopausal, menopausal patients
A study published in the Journal of Cosmetic Dermatology discussed best practices for treating patients with perimenopause- and menopause-related skin conditions. A roundtable discussion was held by two dermatologists, a gynecologist, and a plastic surgeon, who provided their clinical experience and consensus recommendations for treating perimenopausal and menopausal patients.
[Topical estrogens for skin aging. Read more.]
The authors discussed numerous therapies, including hormone replacement therapy (HRT), topical estrogen therapy, topical retinoids, topical cosmeceuticals (moisturizers, signal peptides, growth factors, exosomes), dermal injectables and biostimulators, and energy-based treatments. The panelists found that HRT, topical estrogen, injectable poly-L-lactic acid, injectable hyaluronic acid, and carbon dioxide laser resurfacing are the most effective interventions for treating hormone-related skin changes.
Dermatologists discuss dermatologic changes before and during menopause and the dermatoses that may occur. Read more.
DermWorld Insights and Inquiries: Cocaine-associated plasma cell orificial mucositis — Anything goes
Cocaine-induced plasma cell orificial mucositis (CPCOM) is a recently described disorder that has been increasingly reported. Dermatologists should suspect CPCOM in patients with ulcerative lesions of the nose and upper lip. Although the diagnosis is one of exclusion for infectious and neoplastic disorders by biopsy, culture, or PCR, when recognized, most cases will resolve with corticosteroids and avoidance of cocaine. Read more.
Effects of PRP, minoxidil in patients with androgenetic alopecia
A study published in The Journal of Dermatological Treatment compared the effects of 5% minoxidil, platelet-rich plasma (PRP), and their combination on hair count, telogen/anagen ratio, and vellus hair in androgenetic alopecia (AGA) patients. The study included 45 patients (53.3% female). The PRP and combined therapy groups showed significant improvement in hair count, density, terminal hair count, and anagen ratio. Vellus hair count and density significantly decreased in the combination group. Patient-reported improvement did not differ significantly among groups. According to the authors, PRP improves hair growth in AGA and is more effective when combined with minoxidil, especially in reducing vellus hair.
Efficacy of combination topical finasteride and minoxidil in male androgenetic alopecia. Read more.
Vaccination recommendations in patients with atopic dermatitis taking JAK inhibitors
A study published in the International Journal of Dermatology provided dermatologists with vaccine recommendations for adults and adolescent patients with atopic dermatitis who are receiving, or about to receive, treatment with JAK inhibitors.
Inactivated vaccines are safe and recommended during JAK treatment, although their efficacy may be reduced if the recommended vaccination schedules are not followed, the authors noted. Inactivated vaccines, they continued, should be administered four weeks before JAKi treatment or four weeks after finalization.
[Take the AAD’s Phototherapy and Systemic Therapies for Atopic Dermatitis in Adults on-demand guidelines course and earn CME.]
Live attenuated vaccines are contraindicated unless treatment is temporarily discontinued, according to clinical guidelines. For JAK inhibitors including abrocitinib, baricitinib, and upadacitinib, the use of live attenuated vaccines should be avoided during and immediately before treatment initiation, they said. When live vaccines need to be delivered during active treatment, JAK inhibitors should be paused before and after live vaccine administration. The recommended duration to discontinue medication before live vaccination is based on the drug’s half-life.
Does HPV vaccination change the burden of disease in patients with actinic keratosis? Read more.
Dermatologic signs of eating disorders
A study published in JAAD Reviews characterized the spectrum of dermatologic findings across eating disorder (ED) subtypes and evaluated cutaneous outcomes following therapy. A total of 98 studies describing 2,114 patients were included — with 83% of participants being women. The most common diagnoses were binge-eating disorder/food addiction (37.7%), anorexia nervosa (24%), other specified feeding or eating disorder (21.4%), and bulimia nervosa (16.7%). In total, 20% of patients had psychiatric comorbidities.
[Screening and treating patients with body dysmorphic disorder. Read more.]
Inflammatory dermatoses were most frequent (51.3%), followed by hair (18.6%), nutritional (13.5%), mechanical/behavioral (6.9%), and other categories. The most common findings were xerosis (11%), telogen effluvium (9%), lanugo/hypertrichosis (6%), brittle nails (5.4%), and cheilitis (3.1%). Chronic inflammatory conditions such as atopic dermatitis (36.7%) and acne (6%) were also frequent.
Experts discuss the cutaneous manifestations of Munchausen by proxy, child abuse, and eating disorders. Read more.
